Evaluation of US2019070266 patent, treatment diabetic foot ulcers with Liraglutide
Date
2020-03-16
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Benemérita Universidad Autónoma de Puebla
Abstract
Diabetic foot ulcers are clinical complications that affect to a 15-25% of patients of type-2 diabetes mellitus and are responsible for more hospitalizations than any other complication of diabetes. Authors of US2019070266 patent propose a method for treatment of diabetic foot ulcers. US2019070266 describes a method that consists of the administration of Liraglutide, at a dose of 1.2-1.8 mg, in patients with type 2 diabetes and with at least one risk factor for vascular disease, such as microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, left ventricular systolic dysfunction, left ventricular diastolic dysfunction and ankle/brachial index <0.9. The results of the clinical trials support the therapy’s efficacy; however, the invention is not new considering art state, whereby, new studies will be necessary to determine other administration routes, e.g. topical, dose and time of administration of Liraglutide.
Description
Keywords
Liraglutide, diabetic foot, patent, diabetes, ulcer
Citation
Perez-Santos M. Evaluation of US2019070266 patent, treatment diabetic foot ulcers with Liraglutide. Alianzas y Tendencias BUAP. 2020 Mar 17;5(17):52. Available from: https://www.aytbuap.mx/publicaciones#h.38aimu2eznin
Collections
Document Viewer
Select a file to preview:
Can't see the file? Try reloading